All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML.
During the Society of Hematologic Oncology (SOHO) 2021 Annual Meeting, the AML Hub spoke to Amir Fathi, Massachusetts General Hospital, Boston, US. We asked, How could new immunotherapy modalities in acute myeloid leukemia (AML) change current practice?
How could new immunotherapy modalities in AML change current practice?
Fathi begins by outlining the immunotherapeutic gemtuzumab ozogamicin and the multiple treatment settings in which it is approved. He goes on to describe how and why he uses this therapy in his practice. Finally, Fathi discusses further drug targets and the treatments that correspond to them, such as CD3 and Flotetuzumab.
Immunotherapy approaches in acute myeloid leukemia– interview with Dr. Naval Daver
At the 6th Annual Meeting of the Society of Hematologic Oncology, Naval G. Daver, gave a talk on “Immunotherapy in AML: Anything there.”
How could new treatment combinations improve outcomes in TP53 mutant AML?
During the Society of Hematologic Oncology (SOHO) 2021 Annual Meeting, the AML Hub spoke to Naval Daver, MD Anderson Cancer Center, Houston, US. We asked, How could new...
Subscribe to get the best content related to AML delivered to your inbox